Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891305 | 1.00 | GPR119 (0.45) | GPR119KCNH2XIAPF2PRSS1 | |
| SCHEMBL13026996 | 0.92 | GPR119 (0.48) | GPR119KCNH2XIAPF2PRSS1 | |
| SCHEMBL13067380 | 0.91 | GPR119 (0.45) | GPR119KCNH2XIAPHRH3 | |
| SCHEMBL2891030 | 0.90 | F2 (0.42) | F2PRSS1CMA1CTRCHRH2 | |
| SCHEMBL2891032 | 0.90 | F2 (0.42) | F2PRSS1CMA1CTRCHRH2 | |
| SCHEMBL2900663 | 0.90 | GPR119 (0.45) | GPR119KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2900659 | 0.90 | GPR119 (0.45) | GPR119KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2895540 | 0.90 | GPR119 (0.49) | GPR119KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2897187 | 0.90 | GPR119 (0.49) | GPR119KCNH2HRH3HRH2HRH1 | |
| SCHEMBL2895536 | 0.90 | GPR119 (0.49) | GPR119KCNH2HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | GPR119 1/4885KCNH2 2784/4885XIAP 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.